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Leukotriene B4 12-hydroxydehydrogenase (LTB4DH) catalyzes the oxidation of proinflammatory LTB4 into less bioactive 12-oxo-
LTB4. We recently discovered that LTB4DH was induced by two different natural products in combination. We previously isolated
gallic acid from Radix Paeoniae through a bioactivity-guided fractionation procedure. The purpose of this study is to test the
hypothesis that LTB4DH inducers may suppress neutrophil-mediated inflammation in myocardial infarction. We first isolated the
active compound(s) from another plant, Radix Astragali, by the similar strategy. By evaluating LTB4DH induction, we identified
calycosin and formononetin from Radix Astragali by HPLC-ESI-MS technique. We confirmed that gallic acid and commercial
calycosin or formononetin could synergistically induce LTB4DH expression in HepG2 cells and human neutrophils. Moreover,
calycosin and gallic acid attenuated the effects of LTB4 on the survival and chemotaxis of neutrophil cell culture. We further
demonstrated that calycosin and gallic acid synergistically suppressed neutrophil infiltration and protected cardiac integrity in
the isoproterenol-induced mice model of myocardial infarction. Calycosin and gallic acid dramatically suppressed isoproterenol-
induced increase in myeloperoxidase (MPO) activity and malondialdehyde (MDA) level. Collectively, our results suggest that
LTB4DH inducers (i.e., calycosin and gallic acid) may be a novel combined therapy for the treatment of neutrophil-mediated
myocardial injury.
1. Introduction
Myocardial infarction is a leading cause of morbidity and
mortality worldwide [1, 2]. Myocardial infarction triggers a
sequence of inflammatory reactions involving the infiltration,
activation, apoptosis, and clearance of neutrophils [3]. Thus,
neutrophils play important roles in tissue damage, wound
healing, cardiac remodeling, and scar formation [3–5].
Upon activation, neutrophils release reactive oxygen species,
reactive nitrogen species, proteases, and possibly chemoat-
tractant mediators for recruiting new inflammatory cells
[3]. Interestingly, neutrophil depletion dramatically reduced
infarct size in animal models of myocardial infarction [4, 5].
In addition, neutrophils produce various autacoids, such as
thromboxane B and leukotriene B4 (LTB4), inducing vaso-
constriction and platelet aggregation [6]. LTB4 is generated
from membrane phospholipids by cytosolic phospholipase
A2, 5-lipoxygenase, and leukotriene A4 (LTA4) hydrolase
for recruiting and maintaining neutrophils [7–9]. Current
anti-inflammatory therapies mainly target the formation
and action of inflammatory mediators including LTB4 [10,
11]. Consequently, current LTB4-targeting drugs interrupt
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the progressive recruitment and sustained activation of neu-
trophils within infarcted myocardium [10, 12, 13].
Leukotriene B4 12-hydroxydehydrogenase (LTB4DH) is a
multifunctional enzyme that catalyzes the oxidation of LTB4,
the reduction of 15-oxo-prostaglandins (15-PGs), and the
inactivation of 15-oxo-PGE and lipoxin A4 [14]. LTB4DH
represents an endogenousmechanism for the control of LTB4
levels [15, 16]. Thereby LTB4DH may dampen neutrophil
recruitment and promote the resolution of inflammation
[17]. It is worth noting that several chemopreventive agents
(e.g., dithiolethione) suppress inflammatory processes via
inactivating LTB4 [15, 18]. On the other hand, LTB4DH is
also induced as the fourth class of detoxification enzyme [19].
Collectively, pharmacological induction of LTB4DH expres-
sionmay represent a novel strategy for the inhibition of LTB4-
mediated inflammatory signals in infarcted myocardium.
Herbalmedicines are well characterized for the inhibition
of LTB4 biosynthesis [20–22]. Little is known about the
potential of botanical compounds in the inactivation of LTB4
due to the limitation of the “one-drug-one-target” paradigm.
Therefore, we developed a bias-free genome-wide biological
response fingerprinting (BioReF) approach for the identifica-
tion of target genes from the entire cellular genes in response
to the complex mixture of plant natural products [23]. Thus,
the target genes selected by BioReF may be responsive to two
or multidrugs [24]. As a proof of principle, we previously
identified LTB4DH as target gene for a well-documented
poststroke rehabilitation formulation ISF-1 [23]. In fact, we
discovered that LTB4DH was induced by the combination of
two different herbal extracts (i.e., Radix Paeoniae Rubra and
Radix Astragali). We subsequently identified gallic acid from
Radix Paeoniae for LTB4DH induction [24]. These results
stimulated us to further identify the active compounds from
Radix Astragali for LTB4DH induction within the context of
myocardial infarction.
The present study was designed to test the hypothesis
that LTB4DH inducers may suppress neutrophil-mediated
inflammation in myocardial infarction. LTB4DH induction
may directly decrease LTB4 level and thereby suppress LTB4-
induced infiltration and survival of neutrophils in myocar-
dial infarction. We isolated the active compounds from
Radix Astragali for LTB4DH induction through a bioactivity-
guided fractionation strategy. LTB4DH inducers were evalu-
ated for the potential in the regulation of neutrophil chemo-
taxis and survival. Moreover, the cardioprotective effects
of LTB4DH inducers were also examined in isoproterenol-
induced mice model of myocardial infarction.
2. Materials and Methods
2.1. Antibodies and Biochemical Reagents. Rat monoclonal
Ly6G antibody (RB6-8C5) was purchased from Abcam
(Cambridge, MA, USA). Fluorescein isothiocyanate- (FITC-
) labeled goat anti-rat IgG conjugate and RT-PCR reagents
were purchased from Invitrogen (Carlsbad, CA, USA). Other
biochemicals were purchased from Sigma-Aldrich (St. Louis,
MO, USA) unless otherwise indicated. The oligonucleotide
primers for LTB4DH and 𝛽-actin were obtained from
Genome Research Centre, The University of Hong Kong.
2.2. Cell Culture and Drug Treatment. Human hepatocellular
carcinoma cell line HepG2 was purchased from Ameri-
can Type Culture Collection (Rockville, MD, USA) and
maintained in Eagle’s minimum essential medium (MEM)
containing 10% fetal bovine serum, 100U/mL penicillin, and
100 𝜇g/mL streptomycin in a humidified incubator under
5% CO
2
at 37∘C. HepG2 cells were seeded in 6-well plate
overnight and then treated with gallic acid alone or in com-
bination with herbal fractions, calycosin and formononetin.
After 24 h incubation, the total RNAswere extracted from the
cells treated with indicated drugs and analyzed by RT-PCR
technique.
2.3. Apparatus and Instruments. The HPLC system was
equipped with two Waters 626 Model LC pumps, a Waters
717 Plus autosample injector, a Waters 996 Model photo-
diode array detector (DAD), a Waters 600S model system
controller, and a gradient generator. Herbal profiles were
obtained on a COSMOSIL PAQ-5 C18 column (250mm ×
4.6mm i.d.). The elution was monitored by UV absorption
within a spectrum ranging from 200 to 400 nm. Radix
Astragali extracts were separated by a gradient mixture of
acetonitrile as solvent A and 0.3% acetic acid water as solvent
B in a binary gradient elution system. The gradient elution
was performed as follows: 0–15min, 10–25% A; 15–20min,
25% A; 20–35min, 25–34% A; 35–40min, 34–45% A; 40–
50min, 45% A; 50–65min, 45–65% A; 65–75min, 65–80%
A. The flow rate of mobile phase was 0.8mL/min, and the
column was maintained at 25∘C.
2.4. Fractionation of Radix Astragali Extracts. One hun-
dred grams of dried Radix Astragali aqueous extract from
Lianyungang Xingkang Biotechnology Co., Ltd. (Lianyun-
gang, Jiangsu, China) was extracted with 0.5 liter of Millipore
water at 80∘C for 45min (as Fraction-RAE in Figure 1).
Following the centrifugation at 4000 rpm for 30min, the
supernatant was recovered and precipitated in 75% ethanol.
The soluble materials (as Fraction-EE in Figure 1) were dried
and redissolved in Millipore water for extraction with ethyl
acetate (as Fraction-EAE in Figure 1) and n-butanol (as
Fraction-NB in Figure 1). The water phase was defined as
Fraction-W in Figure 1. Based on the results of RT-PCR
detection, the active fraction was further separated into
nine fractions by semipreparative HPLC as described in
Section 2.3. The fractions generated from Radix Astragali
extract were assayed for LTB4DH induction in combination
with gallic acid as described in Section 2.2.
2.5. Reverse Transcription-Polymerase Chain Reaction (RT-
PCR) Detection. The total RNAs were isolated from drug-
treated cells with TRIzol reagent according to manufac-
turer’s instructions (Invitrogen, CA, USA). cDNA tem-
plates were generated using SuperScript III reverse tran-
scriptase and random hexamer primers (Thermo Scien-
tific, Waltham, MA, USA). The expression of LTB4DH
mRNA (NM 012212) was detected using sense primer, 5󸀠-
GAGCTTCAGGATGGTTCGTA-3󸀠, and antisense primer,
5󸀠-TCATGCTTTCACTATTGTCTTCC-3󸀠, whereas 𝛽-actin
mRNA (NM 001101) was detected as internal control using
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Figure 1: Bioactivity-guided isolation of the active compounds from Radix Astragali for LTB4DH induction. (a) Schematic illustration of the
bioactivity-guided fractionation procedure. The active compounds were isolated from Radix Astragali extract through ethanol precipitation,
extraction with organic solvents, and HPLC separation on a C18 column. The active fractions were highlighted with star (∗) and in bold. (b)
RT-PCR detection of LTB4DH induction. The fractions in combination with gallic acid (GA) were assayed by semiquantitative RT-PCR for
LTB4DH induction in HepG2 cells. (c) HPLC separation and RT-PCR detection of LTB4DH induction. Nine HPLC fractions in combination
with gallic acid (GA)were assayed by semiquantitative RT-PCR for LTB4DH induction inHepG2 cells.The concentration of each fractionwas
normalized against the concentration of raw Radix Astragali (5.18mg/mL). Representative HPLC profile and RT-PCR analysis were shown.
(d) Chemical identification by HPLC-ESI-MS technique. The MS profiles of fraction 6 and 8 were shown. The structures of calycosin and
formononetin were generated by ChemSketch software (http://www.acdlabs.com).
sense primer, 5󸀠-GGCACCACACCTTCTACAATGA-3󸀠, and
antisense primer, 5󸀠-GGAGTTGAAGGTAGTTTCGTGGA-
3󸀠. PCR amplifications were performed as follows: denatu-
ration at 94∘C for 3min, 35 cycles of 94∘C for 30 sec, 57∘C
for 30 sec, and 72∘C for 1.15min and extension at 72∘C for
10min. PCR products were analyzed by gel electrophoresis in
2%agarose containingBiotiumGelRedDNAstain (Hayward,
CA,USA) and visualized underUV light on Bio-RadGel Doc
imaging system (Hercules, CA, USA).
2.6. Chemical Identification by Mass Spectrometry (MS). The
active HPLC fractions were analyzed by HPLC-MS on a
Synergi Hydro-RP C18 (150mm × 4.6mm, 4𝜇m) at the
low rate of 0.7mL/min under the control of an Agilent
HPLC system equipped with a 1525 Separations Module
and a 2998 DAD Unit. Mobile phase compositions were
0.3% (v/v) formic acid in water (A) and acetonitrile (B).
Twentymicroliters of sample was injected and eluted with the
gradient mixture as follows: 0–15min, 10–25% B; 15–20min,
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25% B; 20–35min, 25–34% B; 35–40min, 34–45% B; 40–
50min, 45% B; 50–65min, 45–65% B; 65–75min, 65–80% B.
The eluents were analyzed on an AB Sciex triple quadrupole
mass spectrometer 3200 QTRAP system (Framingham, MA,
USA) equipped with an ESI-Turbo V source operating in
positive ionization mode under the control of Analyst v1.4.2
data system (Applied Biosystems/MDS Sciex, Concord, ON,
Canada). Mass spectrometry was operated under the condi-
tions as follows: drying gas N2, 10 L/min; capillary voltage,
20V; pressure of nebulizer, 30 psi; ion spray voltage, 4.5 kV;
and capillary temperature, 325∘C.
2.7. Isolation of Human Peripheral Blood Neutrophils. Human
neutrophils were isolated from peripheral blood donated
by healthy volunteers following a method described pre-
viously [25]. In brief, peripheral blood was subjected to
dextran sedimentation. Erythrocytes were lysed in hypotonic
solution. Neutrophils were recovered by the centrifugation
in a gradient of Ficoll-Hypaque (GE Healthcare, Uppsala,
Sweden). The cell viability was measured by trypan blue
exclusion. Neutrophils were then resuspended in RPMI1640
medium for the use in the indicated assays.
2.8. Flow Cytometric Analysis of Cell Apoptosis. Neutrophils
were treated with 10 𝜇M LTB4 alone or in combination with
30 𝜇M calycosin and 8 𝜇g/mL gallic acid in RPMI1640/10%
FBS for 3, 6, 9, and 18 h. At the end of drug treatment, the
cells were stained with Annexin V-FITC and PI according
to manufacturer’s instructions. Briefly, the cells were washed
twice with ice-cold PBS and resuspended in 1x Binding Buffer
at a concentration of 1× 106 cells/mL. Cell suspensions (1× 105
cells in 100 𝜇L) were incubated with 5𝜇L of Annexin V-FITC
and 10 𝜇L PI in a 5mL culture tube at room temperature for
20min. The stained cells were immediately analyzed on BD
FACSVerse flow cytometry system (San Jose, CA, USA).
2.9. Assay of Chemotaxis. Freshly isolated humanneutrophils
were treated with 10 𝜇g/mL calycosin and 8 𝜇g/mL gallic acid
individually or in combination. After 24 h incubation, the cell
viability of neutrophils was found to be approximately 50%
based onMTT assay. For the assay of chemotaxis, neutrophils
were labelled by 5 𝜇M Calcein AM (Sigma, St. Louis, MO,
USA). Labeled neutrophils (1.0 × 105) were transferred onto
the upper chamber of a Corning 24-well TransWell plate
with 8 𝜇m pore polycarbonate membrane insert (Tewksbury,
MA, USA). Cell culture medium containing LTB4 (0, 10, or
100 nM) was placed in the lower chamber. After 3 h incuba-
tion, TransWell plate was centrifuged at 200×g for 5min.The
cells in the lower chamber were incubated with the cell disso-
ciation solution for 30min. The fluorescence was measured
on a fluorescence microplate reader at excitation/emission
wavelengths of 485/530 nm (Molecular Devices, Sunnyvale,
CA, USA).
2.10. Isoproterenol-InducedMouseModel ofMyocardial Infarc-
tion. The protocol for the experiments on isoproterenol-
inducedmousemodel of myocardial infarction was approved
by the Committee on the Use of Live Animals in Teaching
and Research (CULATR), The University of Hong Kong.
Thirty male C57BL/6 mice (6–8 weeks old, 20–22 g) were
obtained from Laboratory Animal Unit, The University of
Hong Kong. The mice were allowed free access to standard
rodent chow and clean drinking water. For drug treatment,
the mice were randomly divided into the five treatment
groups (𝑛 = 6) as follows: Control group, receiving saline
and vehicle (0.5mL/day) via i.p. injection for 3 days; ISO
group, receiving saline (0.5mL/day) via i.p. injection for the
first day and isoproterenol (100mg/kg/day, 200𝜇L) via s.c.
injection for another 2 consecutive days; ISO + GA group,
receiving gallic acid (8mg/kg/day, 500𝜇L) via i.p. injection
for 3 consecutive days and isoproterenol (100mg/kg/day,
200𝜇L) via s.c. injection on day 2 and day 3; ISO + CA group,
receiving calycosin (40mg/kg/day, 500𝜇L) via i.p. injection
for 3 consecutive days and isoproterenol (100mg/kg/day,
200𝜇L) via s.c. injection on day 2 and day 3; ISO + CA +
GA group, receiving calycosin (40mg/kg/day) and gallic acid
(8mg/kg/day) in 500𝜇L via i.p. injection for 3 consecutive
days and isoproterenol (100mg/kg/day, 200𝜇L) via s.c. injec-
tion on day 2 and day 3. Isoproterenol was dissolved in 0.9%
saline, whereas calycosin and gallic acid were dissolved in
5% ethanol in 0.9% saline. Isoproterenol was injected 10min
after the injection of calycosin and/or gallic acid as previously
described and dosed [26].
2.11. Histopathological Evaluation of Cardioprotection. Half
of the animals from each interventional group were eutha-
nized by injecting pentobarbital (200mg/kg, i.p.) and fixed
by perfusing 4% paraformaldehyde. The heart tissues were
embedded in paraffin and dissected into 5 𝜇m tissue sections.
Cardiac sections were stained with hematoxylin and eosin
(H&E) stain and examined for gross myocyte injury under
light microscope as previously described [27].
2.12. Immunohistochemical Studies of Neutrophils. Cardiac
sections were boiled in citrate buffer (pH = 6) in microwave
oven for 15min with a 5min interval. Following blocking
in 5% goat serum for 1 h, cardiac sections were probed
with primary antibody against murine Ly6G (1 : 50) at 4∘C
overnight. After 5 washes with PBS, cardiac sections were
subsequently incubated with FITC-conjugated anti-rat IgG
secondary antibody (1 : 200) at room temperature for 1.5 h.
The fluorescent images were acquired on a LSM 700 laser
scanning microscope (Carl Zeiss, Jena, Germany).
2.13. Assay of Myeloperoxidase (MPO) and Malondialdehyde
(MDA). The frozen hearts were homogenized in 1mL PBS
(pH 6.0) supplemented with 0.5% hexadecyltrimethylam-
monium hydroxide and centrifuged at 12,000 rpm at 4∘C
for 20min. The supernatants were recovered for the deter-
mination of MPO activity and MDA level. The protein
concentration in the supernatants was determined with a
Bio-Rad protein assay kit (Hercules, CA, USA) according to
manufacturer’s instructions. The MPO activity was detected
by using a commercial MPO detection kit (Jiancheng Bio-
engineering Institute, Nanjing, China) according to manu-
facturer’s instructions. One unit of MPO activity is defined
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as degrading 1 𝜇mol of hydrogen peroxide at 37∘C. The
MPO activity was determined by measuring the absorbance
at 460 nm on a PerkinElmer UV/VIS spectrophotometer
(Waltham,MA,USA) and expressed as units per gramof total
proteins (U/g proteins).
MDA activity was measured by thiobarbituric acid
assay kit (Jiancheng Bioengineering Institute, Nanjing,
China) according to manufacturer’s instructions. Briefly, the
supernatant was incubated with thiobarbituric acid. The
absorbance at 532 nm was determined on a PerkinElmer
UV/VIS spectrophotometer (Waltham,MA,USA).TheMDA
level was calculated in the format of nmol/mg proteins.
2.14. Statistical Analysis. All results were expressed as the
mean ± SD. Differences between groups were analyzed by
one-way analysis of variance (ANOVA) followed by Tukey’s
test or two-tail paired Student’s 𝑡-test with GraphPad Prism 5
software (La Jolla, CA, USA).The 𝑝 values less than 0.05 were
considered to be statistically significant.
3. Results
3.1. Bioactivity-Guided Isolation of LTB4DH Inducers from
Radix Astragali Extract. Radix Astragali extract was fraction-
ated into different fractions following the bioactivity-guided
fractionation procedure as illustrated in Figure 1(a). Based
on our previous studies, LTB4DH expression was induced
by the combination of the active compounds from Radix
Astragali and gallic acid identified from Radix Paeoniae [24].
Thus, we assayed all Radix Astragali-derived fractions in the
presence of 8𝜇g/mL gallic acid. As shown in Figure 1(b),
neither Radix Astragali extract (RA) nor gallic acid (GA)
induced LTB4DH expression. In combination with 8 𝜇g/mL
gallic acid, interestingly, the initial H
2
O extract (RAE),
ethanol extract (EE), and ethyl acetate extraction (EAE) were
found to markedly induce LTB4DH mRNA expression. We
subsequently separated the Fraction-EAE into 9 fractions
by RP-HPLC on a C18 column. All HPLC fractions were
assayed in combination with 8 𝜇g/mL gallic acid for LTB4DH
induction in HepG2 cell line. Based on RT-PCR detection
(Figure 1(c)), two fractions (i.e., Fraction-6 and Fraction-8)
were found to be active in the induction of LTB4DHmRNA.
Fraction-6 and Fraction-8 appeared to be single peak in
HPLC profiles under different conditions. Thus, Fraction-6
and Fraction-8 were further characterized on a HPLC-MS
system. As shown in Figure 1(d), three major signals, 284.7
[M + H]+, 301.0 [M + H
2
O + H]+, and 569 [2M + H]+, were
detected in the ESI-MS spectrum of Fraction-6 in positive
ion mode. Interestingly, the MS profile of Fraction-6 matches
that of calycosin. On the other hand, Fraction-8 showed two
major positive ions including 268.9 [M + H]+ and 537.1 [2M
+ H]+ matching the MS profile of formononetin.
3.2. Verification of LTB4DH Induction by Commercial Caly-
cosin and Formononetin in Neutrophils. We first examined
the kinetics of LTB4DH expression in response to the
stimulation with the drugs in combination for different
times (i.e., 0, 3, 6, 9, and 18 h). The purified calycosin
fraction (28𝜇g/mL) and commercial gallic acid (8𝜇g/mL) in
combination induced the expression of LTB4DHmRNA in a
time-dependent manner (Figure 2(a)). LTB4DH mRNA was
detectable after 6 h treatment in our assay system.
To confirm the MS identification of the active com-
pounds, we treated human neutrophils with commercial
calycosin (10𝜇g/mL), formononetin (10 𝜇g/mL), and gallic
acid (8𝜇g/mL), individually or in combination, for 24 h.
Total RNAs were extracted from the drug-treated cells
and analyzed by RT-PCR technique for LTB4DH mRNA
expression. As shown in Figure 2(b), commercial calycosin
and formononetin in combination with gallic acid sig-
nificantly induced LTB4DH expression, whereas calycosin,
formononetin, and gallic acid alone showed much weaker
activity.
3.3. Inhibition of LTB4-Induced Neutrophil Survival. To
examine the biological impacts of LTB4DH inducers, we
first investigated the effect of calycosin and gallic acid in
combination on LTB4-mediated cell survival signals. We
treated human neutrophils by LTB4 alone or in combi-
nation with calycosin and gallic acid for different times.
The cells were subsequently stained with FITC-Annex-V
and PI and analyzed by flow cytometry. Compared with
untreated controls, LTB4 effectively prevented neutrophils
from spontaneous apoptosis. In the presence of LTB4, early
apoptotic neutrophils ranged from 3.36% to 5.69% in the first
9 hours, whereas untreated control neutrophils underwent
progressive apoptosis ranging from 7.67% to 11.75%. Impor-
tantly, calycosin and gallic acid in combination effectively
diminished the prosurvival effect of LTB4 on the cell viability
of neutrophils (Figure 3). In particular, after 18 h cotreatment
with LTB4, calycosin, and gallic acid, the number of viable
neutrophils was dramatically decreased from 40.3% to 27.7%,
highly comparable with 26.4% for untreated neutrophils.
3.4. Synergistic Inhibition of Neutrophil Chemotaxis by Caly-
cosin and Gallic Acid. We subsequently examined the effect
of calycosin and gallic acid in combination on LTB4-induced
neutrophil chemotaxis. We treated human neutrophils with
calycosin and gallic acid, individually or in combination, for
24 h. The neutrophils were seeded in the upper chamber of
TransWell plate and allowed to migrate through 8𝜇m pore
polycarbonate membrane towards the cell culture medium
supplemented with LTB4 (0, 10, and 100 nM) over a period
of 4 h (Figure 4(a)). The neutrophils were recovered from
the lower chamber of TransWell plate and quantified by
measuring the fluorescence from preloaded Calcein AM. As
shown in Figure 4(b), calycosin and gallic acid in combi-
nation showed strongest inhibitory effect on LTB4-induced
chemotaxis of neutrophils, although calycosin and gallic
acid alone also prevented the chemotaxis of neutrophils in
response to LTB4 stimulation.
3.5. Synergistic Cardioprotective Effects of Calycosin and Gallic
Acid against Isoproterenol-Induced Myocardial Infarction. To
further determine the cardioprotective effect of LTB4DH
inducers, we treatmicewith calycosin and gallic acid, individ-
ually or in combination, for three consecutive days. On day
2, isoproterenol was injected once a day for two consecutive
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Figure 2: Verification of purified calycosin fraction and commercial compounds (i.e., calycosin and formononetin) for LTB4DH induction
in human neutrophils. (a) LTB4DH induction by purified calycosin fraction and gallic acid (GA) in combination. Human neutrophils were
freshly isolated and treated with purified calycosin fraction (28𝜇g/mL) and gallic acid (GA) (8𝜇g/mL) in combination for indicated time
points. (b) LTB4DH induction by commercial compounds (i.e., calycosin (CA) and formononetin (FM)) and gallic acid (GA) in combination.
Human neutrophils were treated with calycosin (10 𝜇g/mL), formononetin (10 𝜇g/mL), and gallic acid (8 𝜇g/mL), alone or in combination,
for 24 h. LTB4DH expression was assayed by RT-PCR.The mean values of three independent experiments were shown. Significance analysis
was performed by two-tail paired Student’s t-test. ∗∗∗𝑝 < 0.001 (sample versus untreated control).
days to induce myocardial infarction in mice. At the end of
drug treatment, heart tissues were stained with H&E stain.
Compared with untreated controls, isoproterenol induced
the focal or diffused infiltration of lymphocytes, plasma
cells, and polymorphonuclear leukocytes, thereby indicating
myocytolysis. Calycosin and gallic acid alone failed to atten-
uate isoproterenol-induced myocytolysis. Remarkably, caly-
cosin and gallic acid synergistically attenuated isoproterenol-
induced alteration of cardiac morphology (Figure 5(a)).
To examine the in vivo effect of calycosin and gallic acid
on neutrophils infiltration, we probed the cardiac tissues
with specific antibody against neutrophil biomarker Ly6G
and detected by FITC-labeled anti-rat IgG. The neutrophils
were detected and counted under a fluorescence microscope.
As shown in Figures 5(b) and 5(c), calycosin and gallic acid
synergistically eliminated the effect of isoproterenol on neu-
trophil infiltration, although calycosin and gallic acid alone
also showed impressive inhibitory effect on isoproterenol-
induced neutrophil infiltration.
To further verify the in vivo effect of calycosin and
gallic acid on neutrophils infiltration, we determined the
MPO activity in the cardiac tissues after the treatments with
calycosin, gallic acid, and isoproterenol. We found that caly-
cosin and gallic acid in combination significantly prevented
isoproterenol-induced increase in the MPO activity, whereas
neither calycosin nor gallic acid affected the MPO activity in
isoproterenol-treatment animals (Figure 5(d)).
We also examined the effect of calycosin and gallic
acid on lipid peroxidation by measuring MDA levels [28].
We determined the levels of MDA in heart tissues by a
MDA detection kit. As shown in Figure 5(e), gallic acid
alone and in combination with calycosin effectively reduced
isoproterenol-induced increase in the formation of MDA. In
contrast, calycosin alone did not show any inhibitory effect
on isoproterenol-induced increase in the formation of MDA.
4. Discussion
Most of the drugs in the market are basically developed
according to the “one-drug-one-target” paradigm in drug
discovery [29]. We recently discovered that LTB4DH expres-
sion was induced by the coordination between two active
compounds but not either of two compounds alone in human
cells by a genome-wide biological response fingerprinting
(BioReF) approach [23, 24]. With the knowledge of human
genome and proteome, the network approach helped the
design of multitarget drugs [30, 31]. Based on our previous
discoveries, on the other hand, we proposed a new concept
of “multidrugs on one target.” We believe that future drug
development may focus on the synergy of multiple common
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Figure 3: Suppression of LTB4-induced neutrophils survival by calycosin and gallic acid. (a) Human neutrophils were freshly prepared and
were treatedwith 100 nMLTB4 alone or in combinationwith calycosin (CA) (10 𝜇g/mL) and gallic acid (GA) (8 𝜇g/mL) for the indicated times.
The apoptotic cells were detected by staining Annexin V-FITC/PI and profiled by flow cytometry.The apoptotic cells were characterized into
early apoptotic population (lower right panel) and later apoptotic population (upper right panel). (b) Quantitation of neutrophil populations
(viable, early apoptotic, and late apoptotic).
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Figure 4: Synergistic inhibitory effect of gallic acid and calycosin on LTB4-induced chemotaxis of neutrophils. (a) Schematic representation
of neutrophil chemotaxis assay. (b) Quantitation of neutrophil chemotaxis. Human neutrophils were Isolated and treated with gallic acid and
calycosin, individually or in combination, at 37∘C for 24 h. At the end of treatment, neutrophils were loaded with fluorescent probe Calcein
AM. Chemotaxis of neutrophils from the upper chamber towards LTB4 in lower chamber was assayed as outlined in (a).Migrated neutrophils
were quantitated by measuring the fluorescence intensity on a Zeiss fluorescence spectroscopy (Jena, Germany). Data were expressed as the
mean ± SD. Statistical analysis was performed using one-way ANOVA followed by Tukey’s test. ∗∗∗𝑝 < 0.001 (Drugs + LTB versus LTB4).
compounds against one single pharmacological target. By tar-
geting LTB4DH, for example, we previously identified gallic
acid as one of the active compounds from the herb Radix
Paeoniae Rubra through a bioactivity-guided fractionation
strategy [24]. In the present study, we searched for the active
compounds from the other herb Radix Astragali. By assaying
LTB4DH induction in human HepG2 cells, we isolated two
Radix Astragali-derived fractions, namely, Fraction-6 and
Fraction-8, as the active fractions for inducing LTB4DH
expression in combination with gallic acid. HPLC-MS analy-
sis revealed that Fraction-6 and Fraction-8 showed identical
MS profiles to calycosin and formononetin, respectively. One
of the key findings from the current study was that calycosin
and gallic acid in combination could effectively attenuate
isoproterenol-induced myocardial injury in mice.
Neutrophils are known to be activated in the infarcted
myocardium to release free radicals, inflammatory cytokines,
and mediators such as superoxide ions, nitric oxide, TNF-
𝛼, LTB4, and PGE2 [32, 33]. Consequently, infiltrating neu-
trophils may damage surrounding myocytes and endothe-
lial cells via close contacts or release of inflammatory
mediators [3, 34]. As the key example of proinflammatory
mediators, LTB4 is well known to regulate the infiltra-
tion and survival of neutrophils in response to myocardial
injury [9, 35, 36]. Owing to the action of LTB4DH on
LTB4, we postulated that LTB4DH induction might possibly
attenuate neutrophil-mediated myocardial injury via inacti-
vating LTB4. The identification of LTB4DH inducers should
allow the pharmacological interruption of the recruitment
and sustained activation of neutrophils in myocardial infarc-
tion via inactivating LTB4.
In the present study, we first demonstrated that caly-
cosin and gallic acid in combination inhibited LTB4-induced
survival and chemotaxis of human neutrophils in vitro.
We also investigated the effects of two LTB4DH inducers
(i.e., calycosin and gallic acid) on neutrophil infiltration
and subsequent myocardial injury in isoproterenol-induced
mouse model of myocardial infarction. Following the drug
treatment, the cardiac tissues were stained by H&E and
antibody against neutrophil biomarker Ly6G [37]. H&E
staining revealed that calycosin and gallic acid in combina-
tion preserved the cardiacmorphology against isoproterenol-
induced disruption. Fluorescent detection of Ly6G binding
revealed that calycosin and gallic acid in combination sig-
nificantly reduced the infiltration of neutrophils following
isoproterenol-induced myocardial injury. MPO activity is
widely used to indicate the infiltration and activation of neu-
trophils in myocardial infarction [38]. We indeed found that
calycosin and gallic acid in combination significantly reduced
isoproterenol-induced MPO activity in cardiac tissues. On
the other hand, the MDA level serves a common indica-
tor for isoproterenol-induced lipid peroxidation [28, 39].
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Figure 5: In vivo cardioprotective effects of calycosin and gallic acid in combination. (a) H&E histopathological staining of mouse heart
tissues. Five groups (𝑛 = 3) of C57BL/6 mice were treated with vehicle and isoproterenol (ISO); ISO + GA; ISO + CA and ISO + GA + CA.
The cardiac tissues were stained with H&E. Representative images were selected from five groups. (b) Immunohistofluorescence staining of
neutrophil biomarker Ly6G in mouse heart tissues. Following the treatment as described in (a), the heart tissues were probed with Ly6G
antibody and subsequently detected with Alexa Fluor 488-labeled secondary antibody. The cell nuclei were stained with DAPI. The images
were captured under a Zeiss fluorescence microscope. Representative images were selected from five groups. (c) Quantitation of neutrophil
infiltration. Ly6G-positive cells were counted under a Zeiss fluorescence microscope. The mean numbers of neutrophils were shown and
analyzed by one-way ANOVA followed by Tukey’s test. ∗𝑝 < 0.05 (Drugs + ISO versus ISO group). (d) MPO activity in the cardiac tissues.
Following the treatment as described in (a), the heart tissues were homogenized for the assay of MPO activity. The values represent the mean
± SD. ∗𝑝 < 0.05 (Drugs + ISO versus ISO group). (e) MDA levels in the cardiac tissues. Following the treatment as described in (a), the heart
tissues were homogenized for the determination of MDA levels. The values represent the mean ± SD. ∗𝑝 < 0.05; ∗∗𝑝 < 0.01 (Drugs + ISO
versus ISO group).
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Figure 6: Potential impacts of LTB4DH induction on the cellular level and activities of LTB4 in neutrophils. (a) Inactivation of LTB4 by
LTB4DH. (b) LTB4DH induction and subsequent effect on LTB4-mediated cellular signaling pathways.
In our experiments, calycosin and gallic acid in combination
significantly attenuated the effect of isoproterenol on MDA
formation, whereas gallic acid also showed similar inhibition
on MDA formation. These results strongly suggested two
LTB4DH inducers (i.e., calycosin and gallic acid) could
be used to restrict neutrophil infiltration and subsequent
myocardial injury in isoproterenol-induced mouse model of
myocardial infarction.
5. Conclusion
In summary, the present study reported rapid identification of
calycosin and formononetin from Radix Astragali extract as
LTB4DH inducer through a bioactivity-guided fractionation
procedure. Calycosin and gallic acid in combination not only
synergistically induced LTB4DH expression in neutrophils
but also attenuated the effects of LTB4 on the survival and
chemotaxis of neutrophils (Figure 6). Importantly, calycosin
and gallic acid in combination effectively suppressed neu-
trophils infiltration and myocardial injury in isoproterenol-
induced mice model of myocardial infract. Thus, the present
study will promote the pharmacological use of multiple
common compounds in combination in the treatment of
complex myocardial infarction.
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